What is the role of aminosalicylates in Crohn's disease?

• A. They are generally ineffective for Crohn's disease and are primarily used in ulcerative colitis
• B. They are effective to prevent postoperative recurrence in Crohn's
• C. They are used to treat Crohn's fistulas
• D. They are first-line therapy in Crohn's disease

Answer: (A)

Aminosalicylates are best understood as anti-inflammatory drugs that work well when the disease is confined to the colon, as in ulcerative colitis, but they have limited impact in Crohn’s disease, especially when the small intestine is involved. In Crohn’s, the inflammation can occur throughout the GI tract and is often transmural, so the topical, mucosal action of these drugs doesn’t translate into meaningful control. That’s why they aren’t reliable for Crohn’s induction or maintenance therapy and aren’t used to prevent postoperative recurrence or to treat fistulas.

So the statement that captures their typical role is that they are generally ineffective for Crohn's disease and are primarily used in ulcerative colitis. They may be considered for Crohn's limited to the colon in some cases, but they are not a mainstay of Crohn's treatment. The other points—preventing postoperative recurrence, treating fistulas, or serving as first-line therapy—do not align with the common evidence and guidelines for Crohn's management.